Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Gradishar

Showing results (21-30 of 195) with videos related to

Pageof 20
Sort By:
NEJM Evidence|May 30, 2024
Leveraging Molecular Information for Optimal Treatment RecommendationsPatricia Robinson, William J Gradishar
Current Oncology Reports|January 21, 2014
The application of Oncotype DX in early-stage lymph-node-positive diseaseSarika Jain, William J Gradishar
Clinical Breast Cancer|March 20, 2002
A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapyWilliam J Gradishar, Richard Hellmund
JAMA|June 7, 2006
Selective estrogen receptor modulators and prevention of invasive breast cancerWilliam J Gradishar, David Cella
JAMA Oncology|July 17, 2015
Refining Treatment Decisions in Older Patients With Breast CancerLisa Flaum, William J Gradishar
The Oncologist|November 30, 2005
Controversies in the therapy of early stage breast cancerMary Cianfrocca, William J Gradishar
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?Virginia G Kaklamani, William J Gradishar
Cancer Investigation|October 6, 2005
Adjuvant therapy of breast cancerVirginia G Kaklamani, William J Gradishar
Expert Review of Anticancer Therapy|May 2, 2003
Role of capecitabine (Xeloda) in breast cancerVirginia G Kaklamani, William J Gradishar
Clinical Breast Cancer|September 7, 2004
Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancerLisa E Sokolowicz, William J Gradishar
Pageof 20

Showing results (21-30 of 195) with videos related to

Sort By:
Pageof 20
NEJM Evidence|May 30, 2024
Leveraging Molecular Information for Optimal Treatment RecommendationsPatricia Robinson, William J Gradishar
Current Oncology Reports|January 21, 2014
The application of Oncotype DX in early-stage lymph-node-positive diseaseSarika Jain, William J Gradishar
Clinical Breast Cancer|March 20, 2002
A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapyWilliam J Gradishar, Richard Hellmund
JAMA|June 7, 2006
Selective estrogen receptor modulators and prevention of invasive breast cancerWilliam J Gradishar, David Cella
JAMA Oncology|July 17, 2015
Refining Treatment Decisions in Older Patients With Breast CancerLisa Flaum, William J Gradishar
The Oncologist|November 30, 2005
Controversies in the therapy of early stage breast cancerMary Cianfrocca, William J Gradishar
Journal of the National Comprehensive Cancer Network : JNCCN|November 11, 2015
Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?Virginia G Kaklamani, William J Gradishar
Cancer Investigation|October 6, 2005
Adjuvant therapy of breast cancerVirginia G Kaklamani, William J Gradishar
Expert Review of Anticancer Therapy|May 2, 2003
Role of capecitabine (Xeloda) in breast cancerVirginia G Kaklamani, William J Gradishar
Clinical Breast Cancer|September 7, 2004
Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancerLisa E Sokolowicz, William J Gradishar
Pageof 20